Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplitude Inc (AMPL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Amplitude IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Amplitude Inc vs IDEXX Laboratories, Inc. — how do they compare? Amplitude Inc trades at $12.56 (market cap $1.59B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 29.1× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.

AMPLIDXX
Market Cap
$1.59B$46.22B
Sector
TechnologyHealth
52-Week High
$12.69$766.68
52-Week Low
$5.61$526.44
Enterprise Value
$1.45B$47.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplitude Inc

AMPL trades at $12.38, up 1.56% with bullish technical signals from moving averages and ADX indicators. The company shows strong revenue growth reaching $343M in 2025 with a 72% gross margin, though it continues to report net losses. Recent Q2 2026 results missed EPS expectations but beat revenue estimates, with management highlighting AI analytics platform growth and enterprise customer expansion as key drivers.

While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, investors face execution risks from persistent losses, negative cash flow, and ongoing fraud investigations. The stock's valuation appears stretched at 11.6x book value, requiring successful monetization of AI initiatives to justify current levels.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplitude Inc

Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.

Read more on AMPL

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX